Trump Administration Takes Harder Line on Medications for Opioid Addiction
The Trump administration has shifted toward a more skeptical stance on medications like methadone and buprenorphine for treating opioid addiction, despite RFK Jr.'s initial endorsement of these drugs. This represents a reversal of the bipartisan consensus that had emerged over the past decade as overdose deaths surged. The shift concerns public health experts who cite evidence that these medications reduce overdose deaths by over 50%.
Despite Health Secretary Robert F. Kennedy Jr. publicly endorsing evidence-based medications for opioid addiction in April 2025, the Trump administration has taken several actions signaling skepticism toward long-term medication-assisted treatment. SAMHSA issued guidance cautioning against prolonged use of methadone and buprenorphine, the administration appointed a lawyer known for introducing methadone bans, and a Republican congressman introduced legislation to roll back recent flexibilities that expanded methadone access. These actions mark a departure from the bipartisan consensus that had developed in recent years, particularly as opioid overdose deaths reached crisis levels during the COVID-19 pandemic. Addiction physicians and public health experts express concern that the shift prioritizes abstinence-focused approaches over evidence-based treatment, despite data showing these medications reduce overdose mortality by more than 50%. The moves also align with broader Trump administration efforts to reduce reliance on psychiatric medications.
What's missing
The article does not provide specific details on what the SAMHSA guidance actually recommends as alternatives to long-term medication use, nor does it include direct responses from the Trump administration officials or Republican legislators defending their positions on these medications.
What different sources said
- STAT NewsCenter
Are Republicans turning against medications for treating opioid addiction?
Related
Multi-Cancer Blood Test Galleri Fails Primary Trial Endpoint
A major clinical trial of Galleri, a blood test designed to detect multiple cancers early, failed to meet its primary goal of reducing late-stage cancer diagnoses when results were announced in February. Multi-cancer early detection (MCED) tests aim to improve survival rates by identifying disease at earlier, more treatable stages. The failure raises questions about the effectiveness of this promising diagnostic approach despite initial scientific enthusiasm.
Study Uses CPAP Data to Measure Social Jet Lag in Sleep Apnea Patients
Researchers analyzed CPAP adherence records from nearly 3,000 obstructive sleep apnea patients to measure social jet lag—the circadian misalignment between work and free days. About 16-21% of patients showed moderate to severe social jet lag, with prevalence highest in younger and middle-aged adults and declining after age 65. The findings suggest CPAP devices could routinely screen for circadian misalignment, potentially identifying patients who need additional behavioral or activity-based interventions.
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.